Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys to Trim Workforce

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelrys plans to reduce its workforce by up to 15 employees as part of a streamlining of its business, it disclosed in a quarterly earnings document filed with the US Securities and Exchange Commission earlier this month.

The San Diego-based life sciences software solutions company said that it started the process on May 3 and expects to complete it by the end of the year. The total reduction in its workforce will be between 10 and 15 employees.

Accelrys said that it will take a charge of $1 million in connection with the action.

In its SEC document, the firm said that the reduction is "in connection with the streamlining of its operation and integrating its content business."

Max Carnecchia, president and CEO of Accelrys, hinted at the action when the firm released its first-quarter results, in which Accelrys reported a 66 percent increase in revenues year over year. At that time, he said that in connection with the integration of the Symyx acquisition, "we are commencing the restructuring and streamlining of our content product lines in order to better integrate them with our software business."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.